Changes

Jump to: navigation, search

Timeline of vaccines

545 bytes added, 14:27, 1 June 2020
no edit summary
| 2016 (December) || || || Study || A study finds the {{w|rVSV-ZEBOV vaccine}} against {{w|Ebola virus disease}} to be 95-100% effective, making it the first proven vaccine against the disease.<ref name="TL-20161222">{{cite journal |vauthors=Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP|display-authors=6 |title=Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) |journal = Lancet |volume = 389 |issue = 10068 |pages = 505–518 |year = 2017 |pmid = 28017403 |pmc = 5364328 |doi = 10.1016/S0140-6736(16)32621-6 }}</ref><ref name="CNN-2016122">{{cite news |last=Berlinger |first=Joshua |title=Ebola vaccine gives 100% protection, study finds |url=http://www.cnn.com/2016/12/22/health/ebola-vaccine-study/index.html |date=22 December 2016 |work=[[CNN]] |accessdate=25 April 2018}}</ref> ||
|-
| 2019 || November 4 || Influenza || Vaccine approval || "FDA approved Fluzone High-Dose Quadrivalent (Sanofi Pasteur) for adults 65+ years of age—will be available for 2020–21 flu season."<ref>{{cite web |title=FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older |url=http://www.news.sanofi.us/2019-11-04-FDA-approves-Fluzone-R-High-Dose-Quadrivalent-Influenza-Vaccine-for-adults-65-years-of-age-and-older |website=news.sanofi.us |accessdate=1 June 2020}}</ref> || {{w|United States}}
|-
| 2019 || November 22 || Pneumococcal disease || Recommendation || "CDC published updated ACIP recommendations for the use of PCV13 and PPSV23 pneumococcal vaccines for adults age 65 and older."<ref>{{cite web |title=Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices |url=https://www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm |website=cdc.gov |accessdate=1 June 2020}}</ref> || {{w|United States}}
|-
62,434
edits

Navigation menu